Leuprolide ( DrugBank: Leuprolide )


5 diseases
IDDisease name (Link within this page)Number of trials
1Spinal and bulbar muscular atrophy1
2Amyotrophic lateral sclerosis1
3Spinal muscular atrophy1
51Scleroderma1
76Pituitary gonadotropin secretion hyperthyroidism12

1. Spinal and bulbar muscular atrophy


Clinical trials : 18Drugs : 15 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 17 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

2. Amyotrophic lateral sclerosis


Clinical trials : 645Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

3. Spinal muscular atrophy


Clinical trials : 237Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 525Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

76. Pituitary gonadotropin secretion hyperthyroidism


Clinical trials : 29Drugs : 44 - (DrugBank : 14) / Drug target genes : 5 - Drug target pathways : 15 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries